Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Gynecology

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 31 articles: HTML format

Single Articles

January 2026
1. LIAO B, Chen L, Ruan J, Wang R, et al
   Microbiome and gartynecologic cancer.
   Cancer Lett. 2026;636:217940.
   PubMed     Abstract available
   
   
   December 2025
2. XU H, Zeng S, Wang M, Wang Y, et al
   Cytoplasmic SIRT1 enhances the stemness of polyploid giant cancer cells by promoting beta-catenin protein stability and nuclear accumulation in ovarian carcinoma upon neoadjuvant chemotherapy.
   Cancer Lett. 2025 Dec 1:218193. doi: 10.1016/j.canlet.2025.218193.
   PubMed     Abstract available
   
   
   November 2025
3. NI Y, Zhou X, Tang Y, Ren W, et al
   SB225002 Enhances Radiosensitivity in Cervical Cancer via Direct Neutrophil Inhibition and Tumor Cell Suppression.
   Cancer Lett. 2025 Nov 17:218153. doi: 10.1016/j.canlet.2025.218153.
   PubMed     Abstract available
   
   
   
4. SAORIN G, Mauceri M, Caligiuri I, Kamensek U, et al
   Nanoformulation of a Pin1 inhibitor potentiates the efficacy of liposomal doxorubicin in second-line therapy for ovarian cancer.
   Cancer Lett. 2025;637:218128.
   PubMed     Abstract available
   
   
   October 2025
5. EL BABA R, Haidar Ahmad S, Vanhulle C, Vreux L, et al
   Formation of polyploid giant cancer cells and the transformative role of human cytomegalovirus IE1 protein.
   Cancer Lett. 2025;630:217824.
   PubMed     Abstract available
   
   
   July 2025
6. YANG X, Li C, Cheng Y, Qin S, et al
   YY1-Glycolytic Axis Promotes High Glucose-induced Cancer Stemness in Endometrial Cancer: A Multi-Omics Guided Therapeutic Strategy.
   Cancer Lett. 2025 Jul 23:217936. doi: 10.1016/j.canlet.2025.217936.
   PubMed     Abstract available
   
   
   
7. LI J, Shi J, Ding J, Qu W, et al
   Metabolic gatekeeper ACAD9 coordinates linoleic acid metabolism and redox homeostasis via mitochondrial complex I to drive ovarian cancer progression.
   Cancer Lett. 2025;630:217903.
   PubMed     Abstract available
   
   
   
8. DOGRA S, Elayapillai SP, Qu D, Pitts K, et al
   Corrigendum to "Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer" [Cancer Lett. 2023 Dec 1;578:216437].
   Cancer Lett. 2025 Jul 2:217889. doi: 10.1016/j.canlet.2025.217889.
   PubMed    
   
   
   June 2025
9. AO K, Yin M, Lyu X, Xiao Y, et al
   Corrigendum to "METTL3-mediated HSPA9 m6A modification promotes malignant transformation and inhibits cellular senescence by regulating exosomal mortalin protein in cervical cancer" [Cancer Lett. 587 (2024) 216658].
   Cancer Lett. 2025 Jun 3:217827. doi: 10.1016/j.canlet.2025.217827.
   PubMed    
   
   
   May 2025
10. GONG Y, Zhang W, Wang X, Zheng S, et al
    A previously uncharacterized role of TAp73 in ferroptosis by modulating oxidative homeostasis in cervical cancer.
    Cancer Lett. 2025;627:217815.
    PubMed     Abstract available
    
    
    April 2025
11. DURAKI D, Jabeen M, Mao C, Wang L, et al
    A Necrosis Inducer Promotes an Immunogenic Response and Destroys Ovarian Cancers in Mouse Xenografts and Patient Ascites Organoids.
    Cancer Lett. 2025 Apr 29:217738. doi: 10.1016/j.canlet.2025.217738.
    PubMed     Abstract available
    
    
    March 2025
12. LI H, Chatla S, Liu X, Tian Z, et al
    ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination.
    Cancer Lett. 2025;613:217505.
    PubMed     Abstract available
    
    
    February 2025
13. WANG Q, Liu W, Fan Y, Liu S, et al
    Enhancing the Antitumor Effect of MUC16 CART Cells in Ovarian Cancer: The Potential of Oncolytic Adenovirus.
    Cancer Lett. 2025 Feb 25:217588. doi: 10.1016/j.canlet.2025.217588.
    PubMed    
    
    
    
14. TAMURA T, Nagai S, Masuda K, Imaeda K, et al
    mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer.
    Cancer Lett. 2025 Feb 17:217565. doi: 10.1016/j.canlet.2025.217565.
    PubMed     Abstract available
    
    
    
15. GUO M, He M, Dang Y, Lei L, et al
    Predictors of para-aortic lymph node metastasis based on pathological diagnosis via surgical staging in patients with locally advanced cervical cancer: A multicenter study.
    Cancer Lett. 2025 Feb 15:217545. doi: 10.1016/j.canlet.2025.217545.
    PubMed     Abstract available
    
    
    
16. LI X, Yang X, Lin S, Cong H, et al
    Perineural Invasion in Cervical Cancer.
    Cancer Lett. 2025 Feb 14:217561. doi: 10.1016/j.canlet.2025.217561.
    PubMed     Abstract available
    
    
    December 2024
17. LOMELI N, Pearre DC, Lepe J, Argueta DA, et al
    N-acetylcysteine prevents cisplatin-induced cognitive impairments in an ovarian cancer rat model.
    Cancer Lett. 2024 Dec 18:217405. doi: 10.1016/j.canlet.2024.217405.
    PubMed     Abstract available
    
    
    November 2024
18. FIELD NR, Dickson KA, Nassif NT, Marsh DJ, et al
    SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling.
    Cancer Lett. 2024;605:217282.
    PubMed     Abstract available
    
    
    
19. BHOWMIK AD, Shaw P, Gopinatha Pillai MS, Rao G, et al
    Evolving Landscape of Detection and Targeting miRNA/Epigenetics for Therapeutic Strategies in Ovarian Cancer.
    Cancer Lett. 2024 Nov 28:217357. doi: 10.1016/j.canlet.2024.217357.
    PubMed     Abstract available
    
    
    October 2024
20. NING Y, Chen Y, Tian T, Gao X, et al
    S100A7 Orchestrates Neutrophil Chemotaxis and Drives Neutrophil Extracellular Traps (NETs) Formation to Facilitate Lymph Node Metastasis in Cervical Cancer Patients.
    Cancer Lett. 2024 Oct 7:217288. doi: 10.1016/j.canlet.2024.217288.
    PubMed     Abstract available
    
    
    September 2024
21. LEWIS F, Beirne J, Henderson B, Norris L, et al
    Unravelling the biological and clinical challenges of circulating tumour cells in epithelial ovarian carcinoma.
    Cancer Lett. 2024 Sep 26:217279. doi: 10.1016/j.canlet.2024.217279.
    PubMed     Abstract available
    
    
    August 2024
22. WU H, Sun C, Cao W, Teng Q, et al
    Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer.
    Cancer Lett. 2024;602:217192.
    PubMed     Abstract available
    
    
    July 2024
23. JAISWAL SK, Fedkenheuer K, Khamar R, Tan H, et al
    The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer.
    Cancer Lett. 2024 Jul 22:217129. doi: 10.1016/j.canlet.2024.217129.
    PubMed     Abstract available
    
    
    
24. XU J, Lu W, Wei X, Zhang B, et al
    Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment.
    Cancer Lett. 2024;593:216928.
    PubMed     Abstract available
    
    
    June 2024
25. FENG X, Ji Z, Fan X, Kong Y, et al
    ASS1 Enhances Anoikis Resistance via AMPK/CPT1A-mediated Fatty Acid Metabolism in Ovarian Cancer.
    Cancer Lett. 2024 Jun 22:217082. doi: 10.1016/j.canlet.2024.217082.
    PubMed     Abstract available
    
    
    
26. MENG H, Miao H, Zhang Y, Chen T, et al
    YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification.
    Cancer Lett. 2024 Jun 14:217064. doi: 10.1016/j.canlet.2024.217064.
    PubMed     Abstract available
    
    
    
27. YU Y, Lyu C, Li X, Yang L, et al
    Remodeling of tumor microenvironment by extracellular matrix protein 1a differentially regulates ovarian cancer metastasis.
    Cancer Lett. 2024;596:217022.
    PubMed     Abstract available
    
    
    April 2024
28. HA JH, Radhakrishnan R, Nadhan R, Gomathinayagam R, et al
    Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer.
    Cancer Lett. 2024 Apr 18:216891. doi: 10.1016/j.canlet.2024.216891.
    PubMed     Abstract available
    
    
    
29. KAUR P, Shankar E, Gupta S
    EZH2-mediated development of therapeutic resistance in cancer.
    Cancer Lett. 2024;586:216706.
    PubMed     Abstract available
    
    
    March 2024
30. PONGRATANAKUL P, Bremmer F, Pauls S, Poschmann G, et al
    Assessing the risk to develop a growing teratoma syndrome based on molecular and epigenetic subtyping as well as novel secreted biomarkers.
    Cancer Lett. 2024;585:216673.
    PubMed     Abstract available
    
    
    
31. CAO C, Xu Q, Zhu Z, Xu M, et al
    Three-dimensional chromatin analysis reveals Sp1 as a mediator to program and reprogram HPV-host epigenetic architecture in cervical cancer.
    Cancer Lett. 2024 Mar 10:216809. doi: 10.1016/j.canlet.2024.216809.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.